- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Moxifloxacin systemic, Avelox
Synonyms :
Moxifloxacin
Class :
fluoroquinolones
Dosage Forms & Strengths
Injectable solution
400mg/250ml
Tablet
400mg
400
mg
Intravenous (IV)
every day
7 - 14
days
Tablet
Complicated: 400mg orally intravenous every day for 7-21 day
Uncomplicated: 400mg orally intravenous every day for seven days
400mg orally intravenous every day for 5-10 days
pneumonia and septicemia plaque
400mg orally/intravenous every day for 10-14 days
chronic exacerbation
:
400mg orally/intravenous every day for five days
400mg orally/intravenous every day for 5-14 days
400mg orally/intravenous every day
Dosage Forms & Strengths
<18 years: Safety and efficacy not established
Refer adult dosing
may diminish the quinolones absorption
may diminish the quinolones absorption
may diminish the quinolones absorption
may diminish the quinolones absorption
may diminish the quinolones absorption
may decrease the therapeutic effect of antibiotics
may increase the Qt prolonging effect
may diminish the serum concentration of quinolones
may diminish the quinolones absorption
may diminish the quinolones absorption
may increase the Qtc prolonging effect
may increase the Qtc prolonging effect
may increase the Qtc prolonging effect
may increase the Qtc prolonging effect
may increase the Qtc prolonging effect
may increase the photosensitizing agents
may increase the Qt prolonging effect
may diminish the quinolones absorption
may have an increased QTc-prolonging effect when combined with moxifloxacin
may have an increased QTc-prolonging effect when combined with moxifloxacin
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
QTc interval is increased both by lenvatinib and moxifloxacin
may decrease the serum concentration of activated charcoal
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of Moxifloxacin
may increase the Qtc prolonging effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the anticoagulant effect
may diminish the serum concentration of quinolones
may increase the cardiotoxic effect
The presence of magnesium hydroxide reduces moxifloxacin levels by inhibiting its gastrointestinal absorption
trimagnesium citrate anhydrous
trimagnesium citrate anhydrous hinders the gastrointestinal absorption of moxifloxacin, leading to decreased levels
when bromazepam and moxifloxacin are used together, there is a potential reduction in the bromazepam's metabolism
may decrease the serum concentration and decrease in the efficacy
may increase the QTc prolonging effect of QT-prolonging agents
when both drugs are combined, there may be an increased level of serum of moxifloxacin
when both the drugs are combined, the metabolism of carmustine decreases
it enhances the effect of alprazolam by diminishing the metabolism
may enhance the levels of clorazepate by decreasing the metabolism
Frequency defined:
1-10%
Diarrhea
Decreased amylase
Decreased serum glucose
Increased serum ionized calcium
Nausea
Dizziness
Decreased basophils
Increased serum chloride
Increased serum ionized calcium
Prolonged QT interval
<1%
Agranulocytosis
Aplastic anemia
Extrinsic allergic alveolitis
Hepatic failure
Hepatitis
Seizure
Stevens-Johnson syndrome
Thrombocytopenia
Toxic epidermal necrolysis
Acute renal failure
Anaphylactoid reaction
Hemolytic anemia
Pancytopenia
Serum sickness due to drug
Tendon rupture
Post-marketing reports
Agranulocytosis
Aortic aneurysm
Hepatitis
Tendon rupture
Hallucinations
Renal dysfunction
Peripheral neuropathy
Depression
Confusion
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: moxifloxacin
Pronounced: (mox-ih-FLOX-uh-sin)
Why do we use moxifloxacin?
Moxifloxacin is an antibiotic that is used to treat a variety of infections caused by bacteria. It belongs to a class of antibiotics called fluoroquinolones.
Moxifloxacin is used to treat respiratory tract infections, including pneumonia and bronchitis. It can also treat skin and soft tissue infections and urinary tract infections. Moxifloxacin is usually taken by mouth as a tablet or oral suspension.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
